Meyka Pro banner
Cuorips Inc.

Cuorips Inc. Fundamental Analysis (JPX: 4894.T)

4894.TJPX
HealthcareBiotechnology
¥5490.00
¥240.00(4.57%)
Japanese Market opens in 9h 48m

Cuorips Inc. Fundamental Analysis (JPX: 4894.T)

Cuorips Inc. (JPX: 4894.T) shows moderate financial fundamentals with a PE ratio of -39.68, profit margin of -8.86%, and ROE of -23.46%. The company generates $0.1B in annual revenue with strong year-over-year growth of 21.19%.

Key Strengths

PEG Ratio0.80
Current Ratio16.26

Areas of Concern

ROE-23.46%
Operating Margin-9.47%
We analyze 4894.T's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -638.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-638.3/100

We analyze 4894.T's fundamental strength across five key dimensions:

Efficiency Score

Weak

4894.T struggles to generate sufficient returns from assets.

ROA > 10%
-23.69%

Valuation Score

Excellent

4894.T trades at attractive valuation levels.

PE < 25
-39.68
PEG Ratio < 2
0.80

Growth Score

Moderate

4894.T shows steady but slowing expansion.

Revenue Growth > 5%
21.19%
EPS Growth > 10%
-54.68%

Financial Health Score

Excellent

4894.T maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
16.26

Profitability Score

Weak

4894.T struggles to sustain strong margins.

ROE > 15%
-2345.88%
Net Margin ≥ 15%
-8.86%
Positive Free Cash Flow
No

Key Financial Metrics

Is 4894.T Expensive or Cheap?

P/E Ratio

4894.T trades at -39.68 times earnings. This suggests potential undervaluation.

-39.68

PEG Ratio

When adjusting for growth, 4894.T's PEG of 0.80 indicates potential undervaluation.

0.80

Price to Book

The market values Cuorips Inc. at 10.21 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

10.21

EV/EBITDA

Enterprise value stands at -43.36 times EBITDA. This is generally considered low.

-43.36

How Well Does 4894.T Make Money?

Net Profit Margin

For every $100 in sales, Cuorips Inc. keeps $-8.86 as profit after all expenses.

-8.86%

Operating Margin

Core operations generate -9.47 in profit for every $100 in revenue, before interest and taxes.

-9.47%

ROE

Management delivers $-23.46 in profit for every $100 of shareholder equity.

-23.46%

ROA

Cuorips Inc. generates $-23.69 in profit for every $100 in assets, demonstrating efficient asset deployment.

-23.69%

Following the Money - Real Cash Generation

Operating Cash Flow

Cuorips Inc. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.

$0.00

Free Cash Flow

Cuorips Inc. generates weak or negative free cash flow of $0.00, restricting financial flexibility.

$0.00

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

4894.T converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-39.68

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.80

vs 25 benchmark

P/B Ratio

Price to book value ratio

10.21

vs 25 benchmark

P/S Ratio

Price to sales ratio

352.54

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

16.26

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.23

vs 25 benchmark

ROA

Return on assets percentage

-0.24

vs 25 benchmark

ROCE

Return on capital employed

-0.27

vs 25 benchmark

How 4894.T Stacks Against Its Sector Peers

Metric4894.T ValueSector AveragePerformance
P/E Ratio-39.6832.14 Better (Cheaper)
ROE-23.46%550.00% Weak
Net Margin-886.40%30133.00% Weak
Debt/Equity0.000.56 Strong (Low Leverage)
Current Ratio16.265.70 Strong Liquidity
ROA-23.69%3.00% Weak

4894.T outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Cuorips Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

88740.33%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-205.79%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-244.99%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ